GLYCOMIMETICS Inc (GLYC)

Σχετικά με την εταιρεία

GlycoMimetics, Inc. (GlycoMimetics) is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs to address medical needs. The Company is developing a pipeline of glycomimetics that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. The Company’s pipeline includes GMI-17, GMI-1271, E-selectin and CXCR4 antagonist and GMI-151. The Company is developing its lead drug candidate, GMI-17, also known as rivipansel sodium, for the treatment of vaso-occlusive crisis (VOC), a sickle cell disease. The Company completed a Phase II clinical trial, in which 76 patients hospitalized for VOC were treated with the standard of care plus either GMI-17 or placebo.